JPWO2021209822A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021209822A5 JPWO2021209822A5 JP2022562977A JP2022562977A JPWO2021209822A5 JP WO2021209822 A5 JPWO2021209822 A5 JP WO2021209822A5 JP 2022562977 A JP2022562977 A JP 2022562977A JP 2022562977 A JP2022562977 A JP 2022562977A JP WO2021209822 A5 JPWO2021209822 A5 JP WO2021209822A5
- Authority
- JP
- Japan
- Prior art keywords
- cer
- regimen
- pharmaceutical composition
- subject
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010002025 CER-001 Proteins 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 230000006698 induction Effects 0.000 claims 17
- 238000012423 maintenance Methods 0.000 claims 9
- 238000007596 consolidation process Methods 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 2
- 239000003741 agents affecting lipid metabolism Substances 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 201000011200 hepatorenal syndrome Diseases 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 claims 1
- 208000023768 LCAT deficiency Diseases 0.000 claims 1
- 208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011048P | 2020-04-16 | 2020-04-16 | |
| US63/011,048 | 2020-04-16 | ||
| US202063092072P | 2020-10-15 | 2020-10-15 | |
| US63/092,072 | 2020-10-15 | ||
| IBPCT/IB2021/000021 | 2021-01-07 | ||
| PCT/IB2021/000021 WO2021209808A1 (en) | 2020-04-16 | 2021-01-07 | Cer-001 therapy for treating kidney disease |
| PCT/IB2021/000282 WO2021209822A1 (en) | 2020-04-16 | 2021-04-15 | Cer-001 therapy for treating kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522055A JP2023522055A (ja) | 2023-05-26 |
| JP2023522055A5 JP2023522055A5 (https=) | 2024-04-23 |
| JPWO2021209822A5 true JPWO2021209822A5 (https=) | 2024-04-23 |
Family
ID=76034906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562977A Pending JP2023522055A (ja) | 2020-04-16 | 2021-04-15 | 腎臓病を治療するためのｃｅｒ－００１療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11752163B2 (https=) |
| EP (1) | EP4135838A1 (https=) |
| JP (1) | JP2023522055A (https=) |
| KR (1) | KR20230004606A (https=) |
| CN (1) | CN115666720A (https=) |
| AU (1) | AU2021254856A1 (https=) |
| CA (1) | CA3177735A1 (https=) |
| IL (1) | IL297046A (https=) |
| MX (1) | MX2022012906A (https=) |
| WO (1) | WO2021209822A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2984286T3 (es) * | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| IL297046A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Treatment of kidney disease using cer-001 |
| KR20240018430A (ko) * | 2021-04-15 | 2024-02-13 | 아비오닉스 파마 에스에이 | 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용 |
| CA3247588A1 (en) * | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES |
| JP2025519606A (ja) * | 2022-06-10 | 2025-06-26 | アビオニクス ファーマ エスエー | 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法 |
| WO2023237927A2 (en) * | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| EP1545576A2 (en) | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| LT2939683T (lt) * | 2009-02-16 | 2017-03-27 | Cerenis Therapeutics Holding Sa | Apolipoproteino a-i mimetikai |
| EP2673296B1 (en) | 2011-02-07 | 2018-10-24 | Cerenis Therapeutics Holding SA | Lipoprotein complexes and manufacturing and uses thereof |
| AU2012236889A1 (en) | 2011-03-25 | 2013-05-09 | The Trustees Of Columbia University In The City Of New York | Pegylated human HDL particle and process for production thereof |
| US9938312B2 (en) | 2011-03-25 | 2018-04-10 | University Of Georgia Research Foundation, Inc. | Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans |
| JP6438417B2 (ja) | 2013-03-15 | 2018-12-12 | セレニス セラピューティクス ホールディング エスアー | スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法 |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| WO2015173633A2 (en) * | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016085986A1 (en) | 2014-11-24 | 2016-06-02 | Northwestern University | High density lipoprptein nanoparticles for inflammation |
| WO2018022511A1 (en) * | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
| EP3490579B1 (en) * | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
| WO2018029505A1 (en) * | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| FR3100715B1 (fr) | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
| IL297046A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Treatment of kidney disease using cer-001 |
| KR20230004605A (ko) | 2020-04-16 | 2023-01-06 | 아비오닉스 파마 에스에이 | 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법 |
| WO2021209808A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
-
2021
- 2021-04-15 IL IL297046A patent/IL297046A/en unknown
- 2021-04-15 US US17/231,659 patent/US11752163B2/en active Active
- 2021-04-15 WO PCT/IB2021/000282 patent/WO2021209822A1/en not_active Ceased
- 2021-04-15 EP EP21726966.1A patent/EP4135838A1/en active Pending
- 2021-04-15 JP JP2022562977A patent/JP2023522055A/ja active Pending
- 2021-04-15 CA CA3177735A patent/CA3177735A1/en active Pending
- 2021-04-15 KR KR1020227039570A patent/KR20230004606A/ko active Pending
- 2021-04-15 CN CN202180035372.6A patent/CN115666720A/zh active Pending
- 2021-04-15 AU AU2021254856A patent/AU2021254856A1/en active Pending
- 2021-04-15 MX MX2022012906A patent/MX2022012906A/es unknown
-
2023
- 2023-07-21 US US18/356,280 patent/US12364705B2/en active Active
-
2025
- 2025-06-18 US US19/242,564 patent/US20250312366A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Besson et al. | Sclerotherapy with or without octreotide for acute variceal bleeding | |
| Oldenburg et al. | Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol ‘: predictive parameter for therapy duration and outcome | |
| Rodriguez‐Merchan et al. | Emicizumab: Review of the literature and critical appraisal | |
| Lambert et al. | Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B | |
| JP2021515772A5 (https=) | ||
| JPWO2019173530A5 (https=) | ||
| JP2017522316A5 (https=) | ||
| TW200528104A (en) | Combination therapy for hcv infection | |
| Ranaldi et al. | Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review | |
| Shahar | Current therapeutic options in severe Guillain-Barre syndrome | |
| Turpie et al. | Fondaparinux, the first selective factor Xa inhibitor | |
| JPWO2021209822A5 (https=) | ||
| Fazio et al. | Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin | |
| Roozbeh et al. | Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis | |
| Harenberg | Development of new anticoagulants: present and future | |
| Highsmith et al. | Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma | |
| Bondarenko et al. | Efficacy and toxicity of factor Xa inhibitors | |
| JPWO2021123902A5 (https=) | ||
| Ávila-Funes et al. | Guillain-Barre syndrome: etiology and pathogenesis | |
| Steffel et al. | Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors | |
| Moffa et al. | Bromelain after oral or dental procedures: an update | |
| O'Callaghan et al. | Sitaxsentan: an endothelin‐A receptor antagonist for the treatment of pulmonary arterial hypertension | |
| Aziz et al. | Anaphylactic shock at the end of hemodialysis | |
| Fujita | Report of the american heart association (AHA) scientific sessions 2012, Los Angeles | |
| Dummer et al. | Acute management of Kawasaki disease |